OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd. furnished a Form 6-K dated September 14, 2023, reporting the pricing of a registered direct offering. The filing is not a periodic financial report and does not provide operating results for a reporting period.
Offering and Key Financial Metrics
- Security: 2,666,667 ordinary shares.
- Offering price: $1.50 per ordinary share.
- Gross proceeds: The filing states expected gross proceeds of approximately $3.95 million before estimated offering expenses.
- Offering structure: Best-efforts registered direct offering conducted without an underwriter or placement agent to individuals and institutions.
- Closing: Expected on or about September 15, 2023, subject to customary closing conditions.
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity balances, or other operating metrics. The stated share count multiplied by the stated offering price equals approximately $4.0 million, which differs from the approximately $3.95 million gross proceeds stated in the filing; the precise calculation should be verified.
Material Changes Versus Prior Comparable Period
No prior-period financial information or comparable operating metrics are included. The material transaction disclosed is the planned issuance of 2,666,667 ordinary shares, which would dilute existing shareholders upon completion.
Guidance, Outlook, Risks, and Unusual Items
- Completion remains subject to customary closing conditions.
- The offering is conducted on a best-efforts basis, so completion and proceeds are not presented as unconditional.
- Estimated offering expenses will reduce net proceeds, but the filing does not provide their amount.
- No use of proceeds, management outlook, clinical update, or other business guidance is provided in the filing text.
Facts Investors Should Verify
- Whether the offering closed on or about September 15, 2023.
- The final number of shares issued and the net proceeds after expenses.
- The reason the stated gross proceeds of approximately $3.95 million differ from the $4.0 million implied by the disclosed share count and price.
- The offering’s dilution impact and any related changes to the company’s cash runway and capital requirements.
- The use of proceeds, as the filing text does not specify it.